Shivangi Harankhedkar: Gene Therapy and CRISPR Advances in Hemoglobinopathies
Shivangi Harankhedkar, Head Department of Molecular Diagnostics and Research IMS and SUM Hospital at Siksha ‘O’ Anusandhan University, shared a post on LinkedIn:
“It was a privilege to chair the session ‘Gene Therapy and CRISPR-Based Curative Approaches in Hemoglobinopathies’, delivered by Dr Debojyoti Chakraborty, Molecular Scientist, RNA Biology Lab at CSIR – Institute of Genomics and Integrative Biology, at the CME ‘Hemoglobinopathies 2026: Challenges, Care, Cure’, organised at AlIMS Bhubaneswar on the occasion of World Sickle Cell Day.
The session provided an insightful overview of how advances in gene addition and CRISPR-based genome editing are transforming the treatment landscape of sickle cell disease-from lifelong disease control towards the possibility of durable, potentially curative therapy.
The development of BIRSA-101, India’s first indigenous CRISPR-based gene therapy for sickle cell disease, represents a landmark initiative towards making advanced genomic therapies more relevant and accessible within our own healthcare setting.
India and particularly Odisha, with its significant burden of sickle cell disease-looks forward with great hope to its clinical development and successful translation into an affordable treatment for our patients.
Grateful to the organisers, happy that I could attend this encouraging and meaningful academic programme.”
Stay updated with Hemostasis Today.
-
Jun 22, 2026, 16:39Vikram Sinai Talaulikar: Haematology and Female Hormone Health Intersect at Multiple Levels
-
Jun 22, 2026, 16:35Sehrish Chaudhary: Advancing Transfusion Medicine Through Global Collaboration at ISBT 2026
-
Jun 22, 2026, 15:54Ready to Build Your ISTH 2026 Schedule?
-
Jun 22, 2026, 15:36Wolfgang Miesbach: What the Latest Gene Therapy Setbacks Mean for Haemophilia Care
-
Jun 22, 2026, 15:26Suvro Sankha Datta: Advancing Transfusion Medicine Through the Establishment of a Red Cell Genotyping Facility
-
Jun 22, 2026, 15:08Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
-
Jun 22, 2026, 14:41Ilkin Aygun Soyalp: Novel Substrate Recognition Broadens the Biological Role of DPF-3
-
Jun 22, 2026, 14:29Swarnava Roy: Linking Angiotensin Signaling to Oxidative Stress and Organ Damage in Sickle Cell Anemia
-
Jun 22, 2026, 14:14Nicolò Vianini: New Evidence Confirms Bone Marrow as the Primary Site of Thrombopoiesis